Fresenius SE & Co. KGaA (FRE.F) (FRA:FRE) Given a €47.00 Price Target at Sanford C. Bernstein

Fresenius SE & Co. KGaA (FRE.F) (FRA:FRE) has been assigned a €47.00 ($55.29) target price by research analysts at Sanford C. Bernstein in a research report issued to clients and investors on Thursday, Borsen Zeitung reports. The firm currently has a “buy” rating on the stock. Sanford C. Bernstein’s price objective suggests a potential upside of 45.20% from the stock’s current price.

Several other equities analysts also recently weighed in on the company. Nord/LB set a €40.00 ($47.06) target price on Fresenius SE & Co. KGaA (FRE.F) and gave the company a “neutral” rating in a research report on Wednesday, August 5th. DZ Bank reissued a “buy” rating on shares of Fresenius SE & Co. KGaA (FRE.F) in a research report on Wednesday, October 14th. Warburg Research set a €63.00 ($74.12) price objective on Fresenius SE & Co. KGaA (FRE.F) and gave the company a “buy” rating in a research report on Monday, October 5th. Morgan Stanley set a €49.00 ($57.65) price objective on Fresenius SE & Co. KGaA (FRE.F) and gave the company a “buy” rating in a research report on Tuesday, September 1st. Finally, Credit Suisse Group set a €45.00 ($52.94) price objective on Fresenius SE & Co. KGaA (FRE.F) and gave the company a “neutral” rating in a research report on Thursday, October 22nd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and eleven have assigned a buy rating to the company. Fresenius SE & Co. KGaA (FRE.F) presently has an average rating of “Buy” and an average target price of €51.46 ($60.54).

FRA FRE opened at €32.37 ($38.08) on Thursday. The business’s 50 day moving average price is €37.73 and its 200-day moving average price is €40.53. Fresenius SE & Co. KGaA has a fifty-two week low of €60.16 ($70.78) and a fifty-two week high of €80.00 ($94.12).

About Fresenius SE & Co. KGaA (FRE.F)

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.

Featured Story: What is Cost of Debt?

Analyst Recommendations for Fresenius SE & Co. KGaA (FRE.F) (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co. KGaA (FRE.F) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co. KGaA (FRE.F) and related companies with MarketBeat.com's FREE daily email newsletter.